Abstract. Previous studies have indicated that microRNAs (miRNAs/miRs) may participate in the pathogenesis of hypertension. miR-145 has been demonstrated to serve important roles in the development of numerous cardiovascular diseases. However, the specific role of miR-145 in hypertension remains unclear. The present study aimed to investigate the role of miR-145 in spontaneously hypertensive rats (SHR) and rat vascular endothelial cells (RVECs). The results of the present study demonstrated that in the SHR group miR-145 expression was significantly upregulated in the thoracic aorta compared with the control group. Furthermore, a significant decrease in nitric oxide (NO) content was observed in the SHR group compared with the control rats. In RVECs, silencing miR-145 induced a significant increase in the expression of solute carrier family 7 member 1 (SLC7A1) and phosphorylated endothelial nitric oxide synthase, and a dual-luciferase reporter assay confirmed that SLC7A1 is a direct target of miR-145. The results of the present study indicate that miR-145 functions as a key mediator in the pathogenesis of hypertension via targeting SLC7A1, which suggests that miR-145 is a potential target for the treatment of hypertension.
Introduction
Hypertension is a common, highly prevalent hemodynamic syndrome characterized by persistently elevated blood pressure (1) . Hypertension may cause harmful complications in the cardiovascular system and has been characterized as an independent risk factor for numerous cardiovascular diseases (2) . Current antihypertensive medications include calcium channel blockers, phosphodiesterase inhibitors, and nitric oxide (NO), prostaglandin and endothelial receptor antagonists (3) . However, side-effects like affecting the function of kidney and liver and the occurrence of drug-resistance after long-term medication have hindered these treatment to achieve satisfacachieve satisfactory therapeutic effects (3), so there is an urgent requirement for the identification of effective treatments for the management of hypertension.
MicroRNAs (miRNAs/miRs) are small non-coding RNAs that are able to negatively regulate gene expression via binding to the 3'-untranslated region (UTR) of target mRNAs. Previous studies have indicated that miRNAs participate in numerous cellular and molecular events, and the roles served by miRNAs in the pathogenesis of several diseases have been reported (4, 5) . miR-145 has been demonstrated to function as a key regulator in the development of the cardiovascular system. miR-145 is essential for the differentiation (6) and phenotype switching (7, 8) of vascular smooth muscle cells (VSMCs), and the upregulation of miR-145 in endothelial cells in response to shear stress may determine the VSMC phenotype (9) . It has also been observed that miR-145 was aberrantly expressed in the serum of patients with coronary artery disease (10) and acute myocardial infarction (11) , suggesting that miR-145 is a potential biomarker for the diagnosis of cardiovascular diseases. Furthermore, several studies have indicated that the abnormal expression of miR-145 may be associated with the pathogenesis of cardiovascular diseases, including pulmonary arterial hypertension (12) , myocardial infarction (13) and atherosclerosis (14) . The association between miR-145 and hypertension has also been discussed previously (15) ; however, further investigation is required to determine the underlying molecular mechanisms of this association.
NO is considered to be a long-term regulator of arterial pressure (16) . Arginine is a rate-limiting substrate of endothelial NO synthase (eNOS), an enzyme that catalyzes the production of NO in the vascular endothelium (17) (18) (19) . Solute carrier family 7 member 1 (SLC7A1) is an amino acid transporter that regulates arginine metabolism (20) . Previous studies have indicated that an extracellular deficiency of SLC7A1 has been demonstrated to be associated with reduced endothelial function and NO production (21) , which may lead to hypertension.
The present study aimed to investigate the role of miR-145 and SLC7A1 in endothelial cells and a rat model of spontaneous hypertension. It was hypothesized that miR-145 serves an important role in the pathogenesis of hypertension via targeting SLC7A1.
Materials and methods

Animals.
A total of 10 26-week-old male spontaneously hypertensive rats (SHRs; weight, 400±20 g) were used in the present study, and 10 age-matched normotensive male Wistar-Kyoto rats (WKYs) served as the control group. All animals were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China). All rats were housed in cages and kept under standard laboratory conditions (12-h light/dark cycle; temperature of 22±2˚C; relative humidity of 55±5% and access to food and tap water ad libitum). Rats were habituated for 7 days before the experiment. Animal experiments were performed according to the Guide for the Care and Use of Laboratory Animals (Ministry of Health, Beijing, China). The present study was approved by the Animal Care Committee of Henan College of Traditional Chinese Medicine (Zhengzhou, China). The systolic and diastolic blood pressure of the rats was measured using the tail-cuff method every week for 4 weeks. On day 28 the rats were sacrificed, and the thoracic aortas were collected and stored at -80˚C until required.
Cell culture. Rat vascular endothelial cells (RVECs) were isolated from the thoracic aortas of the WKY rats as previously described (22) . Cells were cultured at 37˚C in an atmosphere containing 5% CO 2 in RPMI-1640 (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.).
Cell transfection. The miR-145 inhibitor (sequence, 5'-GUC CAG UUU UCC CAG GAA UCC CU-3'), mimic (sequence, 5'-GGA UUC CUG GGA AAA CUG GAC UU-3') and negative control (sequence, 5'-AGG UAG UGU AAU CGC CUU GTT-3') were purchased from GenePharma (Shanghai, China), and cell transfection was performed using Lipofectamine ® RNAiMAX (Thermo Fisher Scientific, Inc.) according to manufacturer's protocol. Cells were harvested 48 h after transfection for analysis.
NO measurement. The level of NO in the thoracic aortas of the rats was determined using an NO assay kit (S0021; Beyotime Institute of Biotechnology, Haimen, China) according to the manufacturer's protocol.
Dual-luciferase reporter assay. The SLC7A1 3'-UTR complementary DNA fragment containing the putative binding sites for miR-145 and a mutated 3'-UTR of SLC7A1 were amplified and subcloned into a pGL3-luciferase promoter vector (Promega Corporation, Madison, WI, USA). RVECs were seeded into 6-well plates at a density of 1x10 5 cells/well, and were cotransfected with the intended pGL3-luciferase promoter vector and an miR-145 mimic or inhibitor. Following culture for 24 h at room temperature, the cells were harvested and lysed using radioimmunoprecipitation assay buffer (cat. no. P0013E; Beyotime Institute of Biotechnology), and the relative activity of luciferase was determined using a dual-luciferase reporter assay kit (cat. no. RG028; Beyotime Institute of Biotechnology) according to the manufacturer's protocol. The relative Renilla luciferase activities were normalized to firefly luciferase activities, which was used as an internal control for transfection efficiency.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
TRIzol reagent (Thermo Fisher Scientific, Inc.) was used to extract total RNA according to the manufacturer's protocol. RT-qPCR was performed using the One Step SYBR ® PrimeScript™ RT-PCR kit (Takara Biotechnology Co., Ltd., Dalian, China) on an Applied Biosystems 7500 Real-Time PCR system (Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. The thermocycling conditions were as follows: 95˚C for 30 sec; and cycles of 95˚C for 5 sec and 60˚C for 30 sec. Primers were synthesized by Genscript Nanjing, Inc. (Nanjing, China), and the sequences were as follows: GAPDH forward, 5'-TGT GGG CAT CAA TGG ATT TGG-3' and reverse, 5'-ACA CCA TGT ATT CCG GGT CAA T-3'; miR-145 forward, 5'-AAG GGA GTC CAG TTT TCC CAG GAA TCC-3' and reverse, 5'-GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG GAT ACG AC-3'; U6 forward, 5'-CTC GCT TCG GCA GCA CA-3' and reverse, 5'-AAC GCT TCA CGA ATT TGC GT-3'; and SLC7A1 forward, 5'-CTG GAG TGC GAC TTT TGA CG-3' and reverse, 5'-TGT TGA CCA TGG CTG AC T CC-3'. The relative expression of SLC7A1 and miR-154 was analyzed using the 2 -ΔΔCq method (23) with GAPDH and U6 as the internal references, respectively.
Western blotting. RVECs were lysed using radioimmunoprecipitation assay buffer (Beyotime Institute of Biotechnology) according to the manufacturer's protocol. Total protein concentration in the supernatant was measured using a bicinchoninic acid protein assay kit (Beyotime Institute of Biotechnology) according to the manufacturer's protocol. A total of 25 µg of protein samples were separated by SDS-PAGE on an 8% gel and transferred onto polyvinylidene fluoride membranes (EMD Millipore, Billerica, MA, USA). The membranes were then blocked at 4˚C using 5% non-fat milk for 1 h and incubated at 4˚C overnight with the following primary antibodies: Anti-SLC7A1 (1:2,000; 14195-1-AP; Proteintech Group, Inc., Chicago, IL, USA), anti-phosphorylated (p)-eNOS (1:1,000; ab199956; Abcam, Cambridge, MA, USA) and anti-β-actin (1:2,000; ab3280; Abcam). The membranes were subsequently washed and incubated with horseradish peroxidase-conjugated secondary antibodies (1:10,000; ab131368; Abcam) for 1 h at room temperature. The protein bands were then visualized using an enhanced chemiluminescence kit (Beyotime Institute of Biotechnology) on a ChemiDoc™ XRS+imaging system (Bio-Rad Laboratories, Inc., Hercules, CA, USA) according to the manufacturer's protocol.
Bioinformatics. Bioinformatics analysis was performed to predict the target of miR-145. Targetscan (http://www. targetscan.org/) and miRWalk websites (http://zmf.umm.uniheidelberg.de/apps/zmf/mirwalk/micrornapredictedtarget.html) were used.
Statistical analysis. Data are presented as the mean ± standard deviation. The statistical significance of differences between groups were analyzed with SPSS software (version 17.0; SPSS, Inc., Chicago, IL, USA) using one-way analysis of variance and least significant difference post hoc test. All tests were two-tailed and P<0.05 was considered to indicate a statistically significant difference.
Results
miR-145 is upregulated in the thoracic aorta of SHRs.
As expected, systolic and diastolic blood pressure was significantly increased in SHRs compared with WKYs at 2, 3 and 4 weeks (P<0.001; Fig. 1) . Furthermore, the results of RT-qPCR analysis demonstrated that miR-145 was significantly overexpressed in the thoracic aorta of SHRs compared with WKYs (P<0.001; Fig. 2A) . A significant decrease in the expression of SLC7A1 (P<0.001; Fig. 2B ), and the content of NO (P<0.001; Fig. 2C ) was also observed in the thoracic aorta of SHRs compared with WKYs.
Silencing miR-145 increases the expression of SLC7A1 in
RVECs. RVECs were transfected with a miR-145 inhibitor or mimic, and RT-qPCR and western blot analyses were performed to determine the role of miR-145 in RVECs. A significant increase in SLC7A1 expression was observed in RVECs transfected with the miR-145 inhibitor compared with control group (P<0.001), whereas transfection with the miR-145 mimic did not significantly affect SLC7A1 expression (Fig. 3A) . Silencing miR-145 also induced a marked increase in the expression of p-eNOS (Fig. 3B) , an enzyme that controls the production of NO in the vascular endothelium.
SLC7A1 is a direct target of miR-145.
The results of the present study indicated that the expression of miR-145 negatively affects the expression of SLC7A1 in the thoracic aorta of rats, thus a dual-luciferase reporter assay was performed to confirm that SLC7A1 is a target gene of miR-145. We performed bioinformatics analysis in Targetscan and miRWalk websites and revealed that SLC7A1 is a predicted target of miR-145 (Fig. 3C) . The results of the dual-luciferase reporter assay demonstrated that miR-145 mimic transfection significantly decreased the luciferase activity of pGL3-wild type SLC7A1 3'-UTR-transfected RVECs (P<0.001 vs. miR-145 mimic group). miR-145 mimic transfection had no significant effect on pGL3-mutated SLC7A1 3'-UTR luciferase activity (Fig. 3D) . These data indicate that miR-145 directly targets SLC7A1 to negatively regulate the expression of SLC7A1 in vitro.
Discussion
In recent years, increasing evidence has indicated that miRNAs serve important roles in the pathogenesis of hypertension. miR-21 has been demonstrated to reduce blood pressure and alleviate cardiac hypertrophy in SHR models (24) , and miR-27a had been identified to be downregulated in the aortas of SHRs compared with WKYs (25) . In the serum of patients with hypertension, the expression of miR-150 and miR-192 was identified to be significantly downregulated, and the levels of miR-130a, -195 and -92a were markedly upregulated (26) . Furthermore, serum levels of miR-130a and miR-195 have been reported to be positively correlated with blood pressure (26) . The role of miR-145 in hypertension has also been reported; Santovito et al (27) examined the expression of miR-145 in the atherosclerotic plaques of patients with and without essential hypertension, and identified that miR-145 was overexpressed in patients with hypertension. Sala et al (14) investigated a miR-143/miR-145 knockout mouse model and observed that these mice had thinner arteries with reduced vascular tone and smooth muscle layer width, which led to a significantly lower blood pressure. These results suggest that miR-143 and miR-145 serve key roles in regulating VSMC function and blood pressure. In the present study, it was demonstrated that miR-145 was significantly upregulated in the thoracic aorta of SHR compared with WKY rats, which was consistent with the observations of previous studies in humans and rats. However, the expression of miR-145 in the peripheral blood of patients with hypertension may have different patterns to that observed in tissue samples. Kontaraki et al (28) observed a decreased expression of miR-145 in the peripheral blood mononuclear cells of patients with essential hypertension compared with healthy volunteers, and that the mean 24 h diastolic blood pressure was negatively correlated with the expression of miR-145 in these cells. These results indicate that the expression of miR-145 is inconsistent between the blood and blood vessels of patients and rats with hypertension.
Certain target genes of miR-145 have been identified and demonstrated to serve important regulatory roles in a number of cellular processes in previous studies. In colorectal cancer, miR-145 has been identified to suppress the migration and invasion of cancerous cells via targeting erythroblast transformation-specific-related gene (29) . In addition, in nasopha--related gene (29) . In addition, in nasopha- (29) . In addition, in nasopha-. In addition, in nasopharyngeal carcinoma miR-145 has been demonstrated to directly target disintegrin and metalloprotease domain-containing protein 17, and inhibit cancer cell invasion and migration (30) . Furthermore, in osteogenesis miR-145 suppresses osteogenic differentiation by targeting transcription factor Sp7 (31). In isoproterenol-induced cardiomyocyte hypertrophy, miR-145 has been reported to serve a protective role through targeting transcription factor GATA-6 (32) . In the present study, it was observed that the expression of miR-145 was significantly increased in the thoracic aorta of SHRs, whereas the expression of SLC7A1 was significantly downregulated. Silencing of miR-145 in RVECs induced a significant increase in SLC7A1 expression, and a dual-luciferase reporter assay confirmed that SLC7A1 is a direct target of miR-145. These data indicate that miR-145 serves an important role in the pathogenesis of hypertension via targeting SLC7A1, an L-arginine transporter that affects the production of NO and the function of endothelial cells (33) .
NO serves a key role in the cardiovascular system, including dilating blood vessels to relieve hypertension. In the present study, the production of NO was identified to be decreased in the thoracic aorta of the SHR group compared with the control group. Silencing miR-145 was demonstrated to increase the expression of p-eNOS in the SHRs. These results indicate that miR-145 negatively regulates the production of NO through targeting SLC7A1.
In conclusion, the results of the present study indicate that miR-145 participates in the pathogenesis of hypertension via targeting SLC7A1 in vitro and in vivo. Thus, the results of the current study provide novel evidence that miR-145 has a potential application as a therapeutic target for the treatment of hypertension. 
